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Objective: There is limited evidence about the efficacy of cognitive interventions for Alzheimer’s disease
(AD). However, aside from the methodological quality of the studies analyzed, the methodology used in
previous meta-analyses is itself a risk of bias as different types of effect sizes (ESs) were calculated and
combined. This study aimed at examining the results of nonpharmacological interventions for AD with
an adequate control of statistical methods and to demonstrate a different approach to meta-analysis.
Method: ESs were calculated with the independent groups pre/post design. Average ESs for separate
outcomes were calculated and moderator analyses were performed so as to offer an overview of the
effects of bias. Results: Eighty-seven outcomes from 19 studies (n 812) were meta-analyzed. ESs were
small on average for cognitive and functional outcomes after intervention. Moderator analyses showed
no effect of control of bias, although ESs were different from zero only in some circumstances (e.g.,
memory outcomes in randomized studies). Cognitive interventions showed no more efficacy than placebo
interventions, and functional ESs were consistently low across conditions. Conclusions: cognitive
interventions delivered may not be effective in AD probably due to the fact that the assumptions behind
the cognitive interventions might be inadequate. Future directions include a change in the type of
intervention as well as the use of outcomes other than standardized tests. Additional studies with larger
sample sizes and different designs are needed to increase the power of both primary studies and
meta-analyses.
Keywords: Alzheimer’s Disease, nonpharmacological interventions, memory, dementia, activities of
daily functioning
Alzheimer’s disease (AD) is a neurodegenerative condition re-
sulting in significant neuronal loss and a decline in the function of
various neurotransmitter systems (Casey, Antimisiaris & O’Brien,
2010). These brain changes lead to cognitive dysfunction, neuro-
psychiatric symptoms, and difficulties with activities of daily
living (ADLs; Burns & Iliffe, 2009). Memory loss is commonly
the first symptom in AD manifesting insidiously as an inability to
form new memories (Burns & Iliffe, 2009). Dementia due to AD
is formally diagnosed when cognitive or behavioral symptoms
represent a significant decline from previous levels of functioning
and interfere significantly with performance on ADLs such as
working or personal responsibilities (McKhann et al., 2011).
Given that the symptoms of AD result from brain changes and
neurotransmitter deficiencies, pharmacological treatments that at-
tempt to ameliorate the cognitive symptoms have been investi-
gated (Casey et al., 2010; Citron, 2010). However, pharmacolog-
ical treatment has not been shown to have a clinically relevant
effect despite statistically significant effects on clinical trials
(Lanctôt, Rajaram, & Herrmann, 2009). Thus, nonpharmacological
treatments tailored to address cognitive, behavioral, and psycho-
logical symptoms have received much attention in recent years
(Brodaty & Arasaratnam, 2012; Gardette, Coley, & Andrieu,
2010).
Cognitive intervention is an alternative to pharmacological
treatment for people with AD. There are three types of cognitive
intervention: cognitive training, cognitive stimulation, and cogni-
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tive rehabilitation. Cognitive stimulation involves engagement in
group activities such as conversation aimed at enhancing cognitive
and social functioning (Clare, 2003). Cognitive training involves
the use of guided standardized tasks through which people with
AD are taught theory-based strategies and abilities to improve their
cognitive functioning. This type of intervention can be conducted
both individually as well as in a group and can also include
computer-based training (Ballard, Khan, Clack, & Corbett, 2011;
Kurz et al., 2012), and varying difficulty levels are offered based
on the severity of cognitive impairment. Cognitive rehabilitation
(also referred to as cognitive remediation), unlike cognitive train-
ing and cognitive stimulation programs, aims to develop and
implement cognitive strategies applied to specific ADLs through
the use of task-specific techniques and external supports (Grand-
maison & Simard, 2003; Kurz et al., 2012). Through cognitive
rehabilitation programs, people with AD can be taught face-name
associations, routes, the use of an external memory aid, or even
ameliorate behavioral difficulties (Clare, 2003).
The efficacy of cognitive interventions for AD has been exam-
ined recently through three excellent meta-analyses (Clare,
Woods, Moniz Cook, Orrel, & Spector, 2003; Olazarán et al.,
2010; Sitzer, Twamley, & Jeste, 2006) and two successive updates
(Bahar-Fuchs, Clare, & Woods, 2013; Clare & Woods, 2008). The
conclusions of these three meta-analyses are quite different and
even contradictory. After reviewing 11 randomized controlled
trials (RCTs), Bahar-Fuchs et al. (2013) concluded that “no posi-
tive or adverse effects for cognitive training were detected” (p. 25).
Sitzer et al. (2006) concluded that cognitive training produced
large effects on verbal memory after reviewing 19 controlled trials.
After reviewing 179 studies, Olazarán et al. (2010) concluded that
there is a Grade B (consistent low-quality RCTs) recommendation
for cognitive training and cognitive stimulation to improve cogni-
tion (e.g., memory) in people with dementia. So why are the results
from these studies, apparently investigating the same construct, so
different?
One explanation might be the methodology used to conduct the
meta-analysis and calculate ESs. Sitzer et al. (2006) and Bahar-
Fuchs et al. (2013) calculated ESs using change scores and change
standard deviations, but then calculated ESs with raw scores for
part of the outcomes analyzed. In contrast, Olazarán et al. (2010)
calculated ESs using change scores and odds ratios. When ESs are
calculated using change scores, both pre- and posttest standard
deviations are included in the formula (Borenstein, Hedges, Hig-
gins, & Rothstein, 2009). However, when ESs are calculated using
raw scores, only pretest standard deviations are used, so combining
ESs derived from both methods is incompatible. Combining pre-
and posttest standard deviations will produce comparable ESs
when the variability of scores is constant across time periods
(Morris & DeShon, 2002), which is unlikely when a treatment
group is compared to a group with different treatments or no
treatment at all and a Group  Time interaction is expected.
Another explanation for the varying findings is the correlation
between ESs within each study used to calculate the average ES,
which is twofold. On the one hand, the pre/post correlation of each
individual measure is needed to calculate the repeated measures
ES. On the other hand, studies analyzing the effect of a treatment
include both multiple groups and multiple outcomes, which means
that ESs reported are not independent. Bahar-Fuchs et al. (2013)
assumed that the correlation between pre- and posttest scores was
zero, whereas Sitzer et al. (2006) and Olazarán et al. (2010) did not
report how they controlled for the pre/post correlation. Statistical
analyses exist that allow to analyzing the effects of correlational
coefficients on ESs and to modeling for covariance structures
(Tanner-Smith & Tipton, 2014), so analyzing dependent ESs as if
they were independent may lead to incorrect conclusions.
In summary, the three meta-analyses relied on incompatible
statistical measures to calculate and compare ESs, which makes
their results questionable. As Cooper (2010) stated, combining
different outcome measures may obscure “important distinctions
among the outcomes and might have been misleading” (p. 150).
Furthermore, Higgins and Green (2008) added that the use of a
meta-analysis may not be meaningful if the treatments are so
different that an effect estimate cannot be interpreted in any
specific context.
This study, then, has three main goals. First, it will provide a
review of the literature regarding the efficacy of cognitive inter-
ventions to improve cognition in AD. Special attention will be
given to the verbal memory domain as memory impairment is the
initial and most prominent cognitive deficit in AD, and the
amnestic-type is the most common presentation of AD dementia
symptoms (McKhann et al., 2011). Second, our study will conduct
a meta-analysis of these interventions with adequate statistical
methods to reduce the impact of bias. Finally, and as the main goal
of this study, we hope to provide a different approach to meta-
analysis by analyzing ESs according to specific characteristics of
each study design that might potentially affect results in research
studies (Higgins & Green, 2008): randomization, independence of
evaluators, and control condition. Even if outcomes from primary
studies are scaled in the same metric (e.g., raw score metric) in a
meta-analysis, different ESs would be expected between random
and nonrandom studies, between studies with or without blind
assessors or between studies with different control groups (e.g.,
cognitive plus pharma vs. placebo). For example, higher ESs are
expected when a cognitive intervention is compared to a drug-only
group because “comparing two active interventions is likely to
reduce effect size” (Olazarán et al., 2010, p. 172) and because drug
therapy has limited effects on cognition (Birks & Harvey, 2006;
Raina et al., 2008).
Based on previous reviews, we expected to find low to medium
ESs on cognitive and functional outcomes and hypothesized that
studies without control for potential sources of bias would provide
higher ESs compared to controlled studies.
Method and Materials
Procedure
Electronic databases such as PUBMED, PsycINFO, Google
Scholar, and ScienceDirect were explored from February to April
2014 and again in March 2015 using a combination of the search
terms verbal memory, non-pharmacological, and cognitive with
the terms rehabilitation, stimulation, training, treatment, and in-
tervention, with Alzheimer’s disease in the title and abstract. There
was no limitation on date of publication. A global search showed
34,845 results. Forty additional papers were found through a
references-specific search. Figure 1 provides a flow diagram of the
procedure based on the PRISMA Statement (Moher, Liberati,
Tetzlaff, Altman, & the PRISMA Group, 2009).
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2 OLTRA-CUCARELLA ET AL.
Inclusion Criteria
To be included in the meta-analysis, studies had to (a) have a
population with AD in the experimental group; (b) have at least
one outcome, either primary or secondary, related to verbal mem-
ory and/or cognition; (c) be cohort studies where the control group
receives the same treatment, an alternate treatment, or no treatment
at all compared to the experimental group; (d) be published in
English, because excluding studies published in languages other
than English has little effect on treatment effect estimates (Jüni,
Holenstein, Sterne, Bartlett, & Egger, 2002; Morrison et al., 2012);
(e) include participants meeting a probable or possible diagnosis of
AD according to the National Institute of Neurological and Com-
municative Disorders and Stroke–Alzheimer’s Disease and Re-
lated Disorders Association (NINCDS-ADRDA) criteria (McK-
hann et al., 1984; McKhann et al., 2011); and (f) report pre- and
posttest means and standard deviations for both treatment and
control groups. Each paper was evaluated for inclusion indepen-
dently by the first two authors using the criteria stated above. In
case of a discrepancy, the third author reviewed the paper and
decided for inclusion. This happened only for the study by Cipri-
ani, Bianchetti, and Trabucchi (2006), which included only par-
ticipants with mild cognitive impairment (MCI) in the control
group. It was finally included because the experimental group was
comprised of people with AD.
Methodological Quality Assessment
An evaluation checklist designed to include the main points
regarding quality of research methodology from the document
“Strengthening the Reporting of Observational Epidemiological
Studies: STROBE Statement” (Vandenbroucke et al., 2007; see
Appendix A), along with the specific outcomes for each study,
were used to perform separate meta-analyses with a reliable and
standardized research methodology. As in the case of the criteria
for inclusion, the methodological quality of each paper was eval-
uated independently by the first two authors, and discrepancy was
resolved by the third author.
Correlational Meta-Analysis
Statistical Analysis
Average r ES calculation. Because the formula for the ES
variance includes the pre/post correlation, we contacted the authors
and requested the pre/post correlation on each outcome from the
primary studies. We meta-analyzed the available correlations using
the Hedges and colleagues’ random effects methodology described
by Field (2001) (see Appendix B) separately for the experimental
and control groups. We could only meta-analyze correlations for
the outcomes from Clare et al. (2010; k  2), Viola et al. (2011;
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Figure 1. Flow diagram. See the online article for the color version of this figure.
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3COGNITIVE INTERVENTIONS IN AD: META-ANALYSIS
k  2), Bergamaschi et al. (2013; k  4), and Cotelli et al. (2014;
k  13). Results showed a mean ES r  .70 (95% CI [.62, .77],
weighted variance .013) for the experimental groups and a mean
ES r  .76 (95% CI [.69, .83], weighted variance  .011) for the
control groups, with a high and significant heterogeneity among
ESs in both the experimental (Hedges’ Q  10.09, df  3, p 
.018, I2  70.3%) and control groups (Hedges’ Q  10.98, df 
3, p  .012, I2  72.7%).
Sensitivity analysis. Based on the findings of the correlational
meta-analysis, we then performed a sensitivity analysis using
correlational values in ranges of .10 to investigate their impact on
the average ESs. As shown in Appendix C, the average ES re-
mained constant across different correlational values, with a
slightly difference of .03. The average ES using the real correla-
tions compared to the average ES using the average r changed
from 0.29 to 0.27. Based on these results, we calculated the
variance of ESs from both the experimental and control groups
using the average correlational ES for each group, respectively.
Statistical Analysis
Effect size calculation. ESs were calculated with the formula
for independent groups pre/posttest (IGPP) based on raw scores
(Morris, 2008; Morris & DeShon, 2002), which includes the stan-
dard deviation of the pretest as an unbiased estimate of the vari-
ance. ESs for each independent group were corrected using the bias
function formula and weighted by the reciprocal of its sampling
variance (Morris & DeShon, 2002), which was calculated with the
average r separately for the experimental and control groups. All
these statistics were calculated using Microsoft Excel 2007. Al-
though there are different options for calculating ESs in pre/post
designs, the IGPP design was selected for three reasons: (a) it
provides separate ESs for experimental and control groups, so it is
possible to observe ESs in groups with different control interven-
tions; (b) it includes the pre/post correlations of each separate
group for the variance calculations, not the pooled pre/post corre-
lation across groups; and (c) the observed variance of the IGPP
design does not differ from the theoretical variance more than 3%
under most conditions (Morris, 2008).
To compare our results with the three previous meta-analyses,
we calculated the average ES for the following:
• The Mini-Mental State Examination (MMSE; Folstein,
Folstein, & McHugh, 1975)
• Memory outcomes: word-list tasks (Rey Auditory Verbal
Learning Test, Rey, 1964; Hopkins Verbal Learning Test,
Benedict, Schretlen, Groninger, & Brandt, 1998; selective
reminding test, Kessler, Denzler, & Moskowitsch, 1988),
a story recall task (brief story recall, Novelli et al., 1986;
logical memory test, Wechsler, 1987; prose memory,
Capitani, Della Sala, Laiacona, Marchetti, & Spinnler,
1994), and a face–name association task and a memory
battery (Rivermead Behavioral Memory Test, Wilson,
Baddeley, & Cockburn, 2003). Word-list tasks and story
recall tasks were analyzed separately where possible.
• Basic ADLs (Katz Index for Activities of Daily Living,
Katz, Ford, Moskowitz, Jackson, & Jaffe, 1963; Bayer
Activities of Daily Living Scale, Hindmarch, Lehfeld, de
Jongh, & Erzigkeit, 1998; Functional Living Skills As-
sessment, Farina et al., 1999).
• The Instrumental ADL Questionnaire (IADL; Lawton &
Brody, 1969).
• Functional outcomes: including all the functional out-
comes when separate analyses for ADL and IADL could
not be computed (IADL, Katz Index for Activities of
Daily Living, Bayer Activities of Daily Living Scale,
Functional Living Skills Assessment, Advance Activities
of Daily Living Questionnaire, Reuben, Laliberte, Hiris, &
Mor, 1990; and the Rapid Disability Rating Scale–2, Linn
& Linn, 1982). No reference to the functional scales were
obtained from Giordano et al. (2010) and Cotelli et al.
(2014).
Source of bias. Regarding randomization, all but Farina et al.
(2002), Hofmann et al. (2003), Cipriani et al. (2006), Farina et al.
(2006), Giordano et al. (2010), and Viola et al. (2011) randomly
assigned participants to groups.
Regarding independence of evaluators, all but Heiss et al. (1993;
Heiss et al., 1994); Hofmann et al. (2003); Cipriani et al. (2006);
Requena, Maestú, Campo, Fernández, and Ortiz (2006); Tárraga et
al. (2006); and Giordano et al. (2010) reported that cognitive
assessors were blind to group allocation.
For the control condition bias, three comparison groups were
differentiated: (a) a structured cognitive intervention, (b) a placebo
control condition, and (c) a pharma control condition with or
without cognitive intervention or no treatment at all. Farina et al.
(2002); Hofmann et al. (2003); Loewenstein, Acevedo, Czaja, and
Duara (2004); Cipriani et al. (2006); Requena et al. (2006); Tár-
raga et al. (2006); Jelcic et al. (2012); Bergamaschi et al. (2013);
and Cotelli et al. (2014) included a control intervention with
exercises tapping cognitive abilities. The studies with a placebo
control condition included interventions such as social support
(Heiss et al., 1993; Heiss et al., 1994; Davis, Massman, & Doody,
2001), educational information (Cahn-Weiner, Malloy, Rebok, &
Ott, 2003), recreational activities (Farina et al., 2006; Bergamaschi
et al., 2013), semistructured intervention on current affairs and
relevant events (Galante, Venturini, & Fiaccadori, 2007), muscle
relaxation (Clare et al., 2010), creative work (Jelcic et al., 2012),
or motor exercises (Cotelli et al., 2014). Requena et al. (2006),
Tárraga et al. (2006), Clare et al. (2010), Giordano et al. (2010),
Viola et al. (2011), and Fernández-Calvo et al. (2015) included a
control group receiving only pharmacotherapy or no therapy at all.
Statistical Analysis
As in correlational meta-analysis, homogeneity of ESs was
calculated using Hedges’ Q (Morris, 2008) and the I2 statistic
(Higgins & Thompson, 2002). In Hedges’ Q, the null hypothesis is
that all the studies have a common ES. The I2 provides a measure
of the total variation in ESs that is due to the heterogeneity
between studies. Percentages for low, moderate, and high hetero-
geneity are 20%, 50%, and 70% respectively. Whenever I2 yielded
a negative result, it was expressed as 0% (Higgins, Thompson,
Deeks, & Altman, 2003).
As the same participants provided different ESs within each
study, the robust variance estimator (RVE) for correlated ESs was
applied (Hedges, Tipton, & Johnson, 2010; Tanner-Smith & Tip-
ton, 2014). The RVE provides an ES after the statistical depen-
dency among ESs is accounted for. It provides both an uncondi-
tional ES and a multivariable metaregression model to test the
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4 OLTRA-CUCARELLA ET AL.
influence of moderators on ESs. We run the RVE for correlated
effects using the SPSS macro developed by Tanner-Smith and
Tipton (2014). This estimation provides a beta coefficient that is
equal to the unconditional mean ES across studies, and tests the
hypothesis of b  0 with a t test with “number of studies –
parameters” degrees of freedom (in this case, k – 1). To calculate
the RVE, the assumed correlation between all pairs of ES within
studies must be specified. Tanner-Smith and Tipton (2014) suggest
to use an average correlation found in one or more studies, al-
though the cost of choosing an inappropriate value is negligible
because it does not affect the precision of the confidence intervals,
t test or statistical inferences. We, therefore, used the average
correlation within the experimental groups (r  .70). The same
macro was used to test the effect of moderators. As different
designs and different populations were used in each study, the
random effects model was applied (Borenstein, Hedges, Higgins,
& Rothstein, 2009), which assumes that each ES is a sample of a
distribution of possible ES and includes the variance within and the
variance between studies in its calculation.
We calculated the power of each unconditional ES using the
formula described by Hedges and Pigott (2001) for the hypothesis
ES 0. This formula uses the z statistic and the normal cumulative
distribution. For a two-tailed test, Power  1 – (z/2 – Z) 
(–za/2 – Z). The symbol  represents the standard normal
cumulative distribution function and Z is calculated with the
formula ES ⁄ Var* with the random effects variance in the de-
nominator. The results of the unconditional ESs will be presented
except when the robust variance estimator showed that a signifi-
cantly different from zero ES turned out to be nonsignificant or
vice versa. Power of tests from the RVE could not be computed
because, to date, there has not been any work on computing power
with RVE (Elizabeth Tipton, personal communication, October 10,
2015). Power was computed for 23 out of 35 tests.
To test whether the moderators were highly collinear with one
another, we created a binary variable for each study (0  no, 1 
yes) within each of the moderator variables and produced a cor-
relation matrix of the moderator variables at study level (n  19)
so as to give an overview of the intercorrelation between moder-
ators (e.g., correlation between random and nonrandom studies
is 	1; if all the random studies had a placebo control group, then
the correlation between these two moderators would be 1). Results
are presented in Appendix D.
The significance level was set at   .01 for two reasons: first,
because of the high number of tests for statistical significance;
second, because of the small number of studies included for
calculating ESs and for estimating the metaregression coefficient.
Tanner-Smith and Tipton (2014) suggest using an alpha level p 
.01 or p  .001 when using the robust variance estimation with
10–40 studies.
Results
Characteristics and Quality of Studies
Nineteen studies with 812 participants (Ntreatment  356;
NControl  456) were meta-analyzed. For a detailed description of
each study, its participants, duration and the type of measures used
as well as the outcomes obtained, see Table 1.
Table 2 provides a summary of the characteristics of each study
defined as potential biases. The median number of biases was 7
(M  6.16 
 2.22), with a range from 2 to 9. The most frequent
potential bias was the absence of a double-blind design, followed
by the lack of exclusion criteria and the absence of a detailed
explanation of the interventions. Nine studies compared a treat-
ment intervention with a cognitive stimulation control condition,
10 studies compared a treatment intervention with a placebo con-
trol condition, and six studies compared a treatment intervention
with cognitive plus pharma, pharma-only control condition, or no
treatment at all.
Effect Size Comparison
Eighty-seven measures were identified in the 19 studies (see
Figure 2). Sixty-seven (77%) were cognitive measures and 20
(23%) were functional measures. The average ES for all research
outcomes together was small and significantly different from zero
(ES  0.30, var  .00, 99% CI [0.17, 0.44], z  5.77, p  .000)
with high heterogeneity between ESs across studies (I2  76%).
This average ES was taken as a general measure of treatment
effects to give an overview of the variability of ESs. Separate ESs
for experimental and control groups are shown in Appendix E.
The MMSE (Table 3) showed a small ES that was not signifi-
cantly different from zero (k  15; ES  0.41, SE  .16, 99% CI
[	0.06, 0.88], t  2.58, p  .022), whereas the Alzheimer’s
Disease Assessment Scale–Cognitive (ADAS-Cog) subscale
showed a high and nonsignificant ES (k 4; ES 0.77, SE .15,
99% CI [	0.09, 1.63], t  5.21, p  .014). The memory domain
(including all the memory outcomes) showed a small but nondif-
ferent from zero ESs (k  14; ES  0.23, SE  .08, 99% CI
[	0.02, 0.47], t  2.81, p  .015). When analyzed separately, the
story recall tasks showed a small and different from zero ES (k 
6; ES 0.29, var .01, 99% CI [0.00, 0.58], z 2.62, p .009),
whereas ES from the list learning tasks ES (k  5; ES  0.18,
var  .01, 99% CI [	0.11, 0.48], z  1.62, p  .105) and the
Rivermead Behavioral Memory Test (k 6; ES 0.10, var .01,
99% CI [	0.16, 0.36], z  .99, p  .321) were not different from
zero.
Regarding functional outcomes (Table 3), ES was negligible and
not significantly different from zero (k  11; ES  0.15, var 
.01, 99% CI [	0.05, 0.36], z  1.94, p  .053). When calculated
separately, neither ADL (k  8; ES  0.16, var  .01, 99% CI
[	0.11, 0.43], z  1.49, p  .136) nor IADL (k  7; ES  0.09,
var  .01, 99% CI [	0.17, 0.35], z  .90, p  .370) ESs were
different from zero.
Moderator Analyses
Tables 4 and 5 show ESs when studies were combined based on
control for randomization, independence of evaluators, and control
intervention respectively.
Randomization. The MMSE ES was small-to-medium and
not different from zero in both randomized (k  9; ES  0.59,
SE  .26, 99% CI [	0.27, 1.46], t  2.31, p  .050) and
nonrandomized studies (k  6; ES  0.25, var  .02, 99% CI
[	0.10, 0.59], z  1.86, p  .063). ES from memory outcomes
was small and different from zero in randomized studies (k  11;
ES  0.29, var  .01, 99% CI [0.09, 0.49], z  3.72, p  .001)
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but not in nonrandomized studies (k  3; ES  	0.02, var  .02,
99% CI [	0.39, 0.34], z  	0.16, p  .869). Functional ES were
not different from zero in randomized (k  7; ES  0.22, var 
.01, 99% CI [	0.07, 0.50], z  1.94, p  .052) or nonrandomized
studies (k  4; ES  0.07, var  .01, 99% CI [	0.22, 0.25], z 
.62, p  .533). Moderator analyses showed no significant differ-
ences between randomized and nonrandomized studies in memory
ES (all p  .01).
Independence of evaluators. The MMSE ES was small and
not different from zero in studies with (k  8; ES  0.43, var 
.05, 99% CI [	0.02, 0.88], z  1.87, p  .062) or studies without
independent evaluators (k  7; ES  0.33, SE  .18, 99% CI
[	0.32, 0.99], t  1.88, p  .109). ES from memory outcomes
was small and not different from zero in studies with (k  10;
ES  0.26, SE  .10, 99% CI [	0.02, 0.54], t  2.53, p  .032)
and in studies without independent evaluators (k  4; ES  0.17,
var  .02, 99% CI [	0.15, 0.49], z  1.37, p  .169). Functional
ES was not different from zero in studies with (k  9; ES  0.19,
var  .01, 99% CI [	0.04, 0.43], z  2.13, p  .033) or without
independent evaluators (k  2; ES  0.00, var  .03, 99% CI
[	0.42, 0.42], z  .01, p  .993). Moderator analyses showed no
significant differences between studies with or without indepen-
dent evaluators in any of the variables (all p  .01).
Comparison conditions. The MMSE ES was not different
from zero when the control group received cognitive stimulation
(k  8; ES  0.09, var  .03, 99% CI [	0.38, 0.55], z  .48, p 
.628), a placebo intervention (k  8; ES  0.17, var  .07, 99%
CI [	0.49, 0.83], z .67, p .505), or only pharma (k 4; ES
0.69, SE  .25, 99% CI [	0.78, 2.16], t  2.74, p  .071). ES
from memory outcomes was small and different from zero in
studies with a placebo control condition (k 10; ES 0.22, var
.01, 99% CI [0.02, 0.42], z  2.79, p  .005), but not in studies
with a cognitive control condition (k  7; ES  0.37, var  .04,
99% CI [	0.15, 0.89], z  1.85, p  .063). It was not possible to
calculate ES from memory outcomes in studies with pharma-only
control condition due to a lack of outcomes (one outcome in one
study). ES from functional outcomes was not different from zero in
studies with a cognitive control condition (k  4; ES  	0.04,
var  .01, 99% CI [	0.35, 0.28], z  	.29, p  .766), a placebo
control condition (k  6; ES  0.24, var  .01, 99% CI [	0.05,
0.53], z  2.16, p  .030), or pharma-only control condition (k 
2; ES 0.19, var .05, 99% CI [	0.38, 0.77], z .87, p .382).
Metaregression analyses showed no effect of the control condition
in any of the variables analyzed (all p  .01).
Conclusions
This meta-analysis intended to extend the results provided by
previous meta-analyses regarding the effectiveness of cognitive
interventions for AD by analyzing ESs with a different methodol-
ogy: calculating ESs in a common metric, calculating the average
ES using metaregression for correlated ESs and analyzing potential
sources of biases as moderator variables.
When the ESs of all the selected studies were combined to get
an average ES, the results showed low efficacy and high hetero-
geneity on ESs. The effects of interventions on cognitive and
functional outcomes were negligible to low. Mean ESs for mea-
sures of general cognitive functioning were higher than those
reported by Bahar-Fuchs et al. (2013; ES  0.10) and similar toTa
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10 OLTRA-CUCARELLA ET AL.
those reported by Olazarán et al. (2010; ES  0.30–0.59) and
Sitzer et al. (2006; ES  0.37–0.40), although not significantly
different from zero.
Several factors could explain this difference in ESs. First,
Bahar-Fuchs et al. (2013) included only RCT, whereas our meta-
analysis includes studies with different designs, which increases
heterogeneity. Second, Bahar-Fuchs et al. reported ESs for mild to
moderate AD and vascular dementia, whereas we analyzed studies
of participants with AD only, except for one study where the
participants had mixed vascular  AD dementia (Clare et al.,
2010) and one with participants with AD and MCI (Loewenstein et
al., 2004).
Regarding the ADLs, we found a higher ES than the one reported
by Bahar-Fuchs et al. (2013; ES  0.00) and smaller than the one
reported by Olazarán et al. (2010; ES  0.37–0.41) and Sitzer et al.
(2006; ES  0.32–0.75). As heterogeneity among functional ESs
was low to moderate (I2  0.00 –0.50), and mean ESs for
functional outcomes were consistent across methodological de-
signs (ES  	0.04 –0.29), our results suggest that the effect of
cognitive stimulation on functional outcomes for AD is low, in
line with other findings regarding the absence of transfer to un-
trained situations. As dementia is diagnosed when cognitive im-
pairment interferes with ADLs, our results highlight the need to
develop cognitive interventions that provide persons with AD with
strategies to cope with ADLs and further suggest that the kind of
cognitive interventions published to date may be ineffective to
improve memory, cognition, and functionality.
Several factors could explain our results. First, measures of general
cognitive outcome are too broad and do not focus on the outcome of
interest (e.g., the MMSE for assessing verbal memory). A measure of
general cognitive functioning, thus, would have limited usefulness as
it is likely unrelated—or only tangentially related—to what has been
trained during the intervention. For example, Loewenstein et al.
(2004) and Davis et al. (2001) trained their participants in a face–
name association task, whereas Giordano et al. (2010) trained their
participants using reality orientation therapy. It is unlikely that a
measure of general cognitive functioning can reliably identify any
improvement in memory regarding face–name association, even
though the participant identifies correctly all the items included in the
intervention task. In the case where reality orientation therapy is
effective and the participants improve their time orientation, it is likely
that some improvements in measures such as the MMSE are evident,
but its functional correlate with ADLs is uncertain. Thus, we suggest
that the efficacy of interventions be measured through the achieve-
ment of personalized goals rather than through the use of general tests
such as the MMSE or the ADAS-Cog subscale to truly impact the
needs of people with AD dementia. Some examples of this type of
intervention were carried out by Clare et al. (2010) and Zanetti et al.
(2001). Clare et al. (2010) performed an intervention focused on
relevant goals to the individual and found that participants who
received personalized intervention rated higher on both performance
and satisfaction after intervention, whereas control groups did not
show any significant change. Zanetti et al. (2001) trained their par-
ticipants in basic and instrumental ADLs and analyzed the impact of
the intervention through the decrease in the time needed to perform
the task.
A possible explanation for the absence of significant functional
improvements is that none of the studies in the meta-analysis included
a treatment group trained by an occupational therapist in specific
ADLs. As occupational therapists are skilled in improving ADLs
through meaningful activity training programs including the prefer-
ences, interests, and the strengths of people with dementia (National
Collaborating Centre for Mental Health, 2007), any rehabilitation
program seeking to improve functionality and independence must
include these health workers within the professional staff. The only
work that included occupational therapists was the one by Fernández-
Calvo et al. (2015), but their specific intervention on ADLs was not
detailed. If the rationale for a memory intervention is that any im-
provement in cognition will transfer to untrained situations such as
ADLs, then probably nonsignificant results are likely to be reported
because of a lack of transfer to untrained situations (McDaniel &
Bugg, 2012).
Another explanation could be the limited sensitivity of func-
tional scales and questionnaires in general to small although sig-
nificant changes for individual participants. The use of group
Table 2
Characteristics of the Studies Included in the Meta-Analysis
Source of bias
Study reported in Table 1
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 %
Groups 4 4 3 2 4 3 2 2 3 3 2 2 3 2 2 2 2 2 2
Randomization Y Y Y N Y N Y N N Y Y Y Y N N Y Y Y Y 31.58
Double blind N N Y N Y N N N N N N N N N N N N Y N 89.47
Independence of assessors N N Y Y Y N Y N Y N N Y Y N Y Y Y Y Y 36.84
Control intervention Y Y Y Y N Y N Y N Y Y N N N N Y Y Y N 42.10
Placebo intervention Y Y N N Y N Y N Y N N Y Y N N N N Y N 57.89
Inclusion criteria N N N Y N N N Y Y N Y Y Y Y Y Y N Y Y 42.10
Exclusion criteria N N N Y N N N N Y Y N N Y N N Y N N N 73.68
Control of selection bias N Y N Y Y N Y N N N N N Y Y Y Y Y Y Y 42.10
Follow-up assessment N N N Y Y Y Y N Y Y N Y Y Y N N Y Y N 42.10
Standardized assessment Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 0
Functional assessment N N N Y Y N N Y Y N N Y Y Y N Y Y Y N 47.37
Detailed explanation of intervention N N Y N Y Y N N N N N N N N N Y Y Y Y 63.16
Attrition causes N Y N Y Y N N N Y Y Y Y Y N Y N N N N 52.63
 bias 9 7 7 4 3 9 7 9 5 7 8 5 3 8 8 4 5 2 7
Note. Y  yes; N  no (bias).
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11COGNITIVE INTERVENTIONS IN AD: META-ANALYSIS
means instead of single-subject data could mask clinically signif-
icant changes that cannot be observed in standardized tests and
questionnaires. The use of data from a group where no improve-
ments are found will suggest that the intervention is not effective
(which is the case in this work); however, analyzing the data from
individuals within a group may provide insights about the individ-
ual’s characteristics related to the efficacy of such intervention.
Given the importance of functional ADLs, we consider that future
works should compare a cognitive intervention only to an intervention
combining cognitive  functional activities focusing on training
participants in ADLs (e.g., preparing meals) and significant relevant
goals (e.g., finding personal belongings, dressing), and measure their
improvement using outcomes such as the time required to perform
each task, the number of errors on each task, the number and type of
external help needed, or the satisfaction derived from performing
those tasks (Clare, Evans, Parkinson, Woods, & Linden 2011; Clare
et al., 2010; Zanetti et al., 2001). It is important to note that we do not
suggest that interventions must be carried out according to the pre-
defined outcome measure. Rather, outcomes specifically related to
trained situations should be selected to measure the efficacy of any
given intervention before even initiating it. Our hypothesis is that ESs
will become medium to large for variables related to trained situations
and will remain low for measures such as the MMSE or the IADL
questionnaire.
Differences in ES Due to Methodological Bias
Contrary to our expectations, we could not find differences in ESs
for cognitive or functional outcomes when participants are randomly
assigned to groups, participants are assessed by personnel blinded to
group allocation or when a treatment intervention is compared to
another cognitive intervention, a placebo intervention or an alternate
intervention (cognitive plus pharma, pharma-only, or no treatment at
all). Olazarán et al. (2010) found that the effects of multicomponent
interventions were similar to the effects obtained by drug therapy and
suggested that these interventions should be complementary. Never-
theless, one would expect a higher ES when the cognitive intervention
is compared to a drug-only group (Birks & Harvey, 2006; Olazarán et
al., 2010; Raina et al., 2008). According to these findings, there would
be no reason for recommending cognitive interventions or other kind
of interventions such as social support or mental stimulation over
pharmacotherapy, as ESs in the latter case were not different from
zero. However, it cannot be concluded that there are no beneficial
effects of cognitive intervention over pharmacotherapy alone or in
combination with cognitive stimulation because the small number of
studies and outcomes reduced the power to find significant effects.
Contrary to our expectations, studies that did not control for bias
did not show higher ESs. Overall, average ESs with and without
control for bias showed that the effects of the interventions on mea-
sures of general cognitive functioning were similar to those on func-
tional outcomes, which supports the conclusions of others who ques-
tion the efficacy of cognitive training as it has been performed in
previous research (Bahar-Fuchs et al., 2013; McDaniel & Bugg,
2012). These results are in line with other meta-analyses assessing
cognitive interventions in other populations with neurologic diseases
such as multiple sclerosis (Magalhães et al., 2014) or brain injury
(Rohling, Faust, Beverly, & Demakis, 2009), which found no signif-
icant effects of interventions on memory.
Figure 2. Forest plot with all outcomes and studies.
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13COGNITIVE INTERVENTIONS IN AD: META-ANALYSIS
This work has, notwithstanding, several limitations. One of the
main caveats is that some relevant work in the area of cognitive
interventions on AD was not included because it failed to meet our
requirements for diagnostic criteria or pre/post statistics (Gaitán et al.,
2013; Kurz et al., 2012; Metitieri et al., 2001; Olazarán et al., 2004;
Onder et al., 2005; Simmons-Stern, Budson, & Ally, 2010; Zanetti et
al., 2001). All the participants met the Neurological and Communi-
cative Disorders and Stroke–Alzheimer’s Disease and Related Disor-
ders Association’s criteria for AD, which are biased toward memory
impairments. However, there exist atypical AD presentations such as
focal posterior cortical atrophy or progressive aphasia in which epi-
sodic memory could either be spared during the initial phases (Galton,
Patterson, Xuereb, & Hodges, 2000) or be so pronounced that suggest
a critical diagnostic feature (Lambon Ralph, Patterson, Graham, Daw-
son, & Hodges, 2003). In the absence of a detailed explanation of
complementary exams (e.g., magentic resonance images, biomark-
ers), the different characteristics of persons diagnosed with AD could
account for some of the variability in the effects of treatment. We
recommend that future research use diagnostic criteria including both
biomarkers and neuropsychological testing specifically designed for
target populations, thus increasing sensitivity and specificity (Becker,
Boller, Lopez, Saxton, & McGonigle, 1994; Lopez, McDade, Riverol,
& Becker, 2011) instead of using more general criteria such as those
included in the Diagnostic and Statistical Manual of Mental Disor-
ders, Fourth Edition and Fourth Edition Text Revision (American
Psychiatric Association, 1994, 2000).
Another limitation to this study, which could explain the failure to
find any significant effect, is the reduction of power due to the small
number of outcomes and studies. For example, when comparing ESs
for cognitive outcomes between random and nonrandom studies, we
could only compare 37 variables from 13 random studies with seven
variables from five nonrandom studies. We cannot conclude that there
are no significant differences between ESs, because we had not
enough power to detect such differences (Hedges & Pigott, 2001).
The average power of our analyses was 0.27 (median 0.23), which
limits our conclusions. This prevents us from asserting that ESs are
not different from zero or that there are no differences in ESs when
studies are compared according to methodological biases; rather, our
analyses were underpowered to detect such an affect. However, if data
from studies with lower risk of bias (randomization and independent
assessors) are taken as closer to the real ES, our results indicate that
the average ES is small for cognitive (ES  0.44) and functional
(ES  0.22) outcomes.
Including underpowered studies in meta-analysis is not uncom-
mon. Turner, Bird, and Higgins (2013) found that in 70% of a
Cochrane meta-analyses review all studies were underpowered,
whereas 66% of the meta-analyses themselves were underpow-
ered. As power in random effects model is affected by both the
number of studies and the variance between studies (Cohn &
Becker, 2003), which changes as a function of sample size, addi-
tional studies with larger sample sizes are needed to more accu-
rately meta-analyze the efficacy of cognitive interventions in AD
according to moderator variables and powered studies.
We cannot rule out the possibility that other sources of bias
affected the ESs. For example, while the majority of studies
compared at least two groups of AD participants, Hofmann et al.
(2003) compared AD participants with a healthy control group,
and Cipriani et al. (2006) included a control group with MCI.
Other source of bias could be the modality of the intervention
delivered; for example, Hofmann et al. (2003), Cipriani et al.
(2006), Tárraga et al. (2006), and Galante et al. (2007) reported
delivering the cognitive intervention using some kind of software
for cognitive stimulation.
Regarding the pharmacological interventions, the majority of stud-
ies in this meta-analysis included participants treated with stable doses
of cholinesterase inhibitors (donepezil or memantine), whereas Farina
et al. (2002) and Cahn-Weiner et al. (2003) did not report any
pharmacological treatment, Jelcic et al. (2012) and Hofmann et al.
(2003) included participants with no pharmacological treatment, and
Heiss et al. (1993; Heiss et al. 1994) included a group with dietary
supplement and other group with a drug similar to vitamin B6.
Because pharmacological treatments used to enhance cognition in AD
have shown small effects on cognitive and functional outcomes
(Raina et al., 2008), we cannot rule out that the ESs reported here are
a consequence of these interventions. It is worth noting that ESs for
cognitive (ES  0.42) and functional (ES  0.19) variables from
studies in which patients were taking cholinesterase inhibitors are still
small and negligible, respectively.
This is, to our knowledge, the first meta-analysis on cognitive
interventions in AD that calculates ESs controlling for their intercor-
relations and measuring the effects of moderators such as the com-
parison groups. The main finding is that ESs for functional and
cognitive outcomes were negligible to low and that did not differ
when potential sources of bias were controlled (e.g., MMSE or
functional ESs), an issue that future research should take into account
when reporting findings. As pointed out by a reviewer, some works
Table 5
Effect Size Comparison With the Control Group Included
Control group Study as reported in Table 1 Outcomes Q df I2
MMSE
Cognitive stimulation 4, 6, 8, 10, 11, 18 6 5.11 5 2%
Placebo 1–3, 9, 12, 16–18 10 12.29 7 43%
Pharma 10, 11, 14, 15 5 4.56 3 34%
Functional
Cognitive stimulation 4, 7, 8, 18 6 1.07 3 0%
Placebo 5, 9, 12, 16–18 11 7.54 5 34%
Pharma 14, 19 3 1.99 1 50%
Memory
Cognitive stimulation 4, 7, 8, 11, 18 10 7.06 4 43%
Placebo 1–3, 5, 9, 12, 13, 16–18 21 10.16 9 11%
Note. MMSE  Mini-Mental State Examination.
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compared a cognitive training group with a control group receiving
cognitive stimulation, whereas other studies compared an experimen-
tal group receiving cognitive stimulation with a control group receiv-
ing placebo or pharma only. Thus, cognitive stimulation is used as an
experimental intervention in some studies and as a control interven-
tion in some others. This type of comparisons will not estimate the
same ES parameter and limits the generalization of our results. Our
moderator analyses showed no differences in ESs according to the
control group intervention, probably due to power issues, but further
research is needed to clarify whether cognitive interventions are more
effective than pharma only or placebo, or even differently effective
between each other (e.g., cognitive training vs. cognitive stimulation).
We suggest that interventions should focus on personalized goals and
should include measures related to trained situations instead of or in
addition to standardized outcomes.
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Appendix A
Methodological Quality Indices for Research Studies
Each item of the index is scored as Y  “yes” or N  “no” for
each individual research study.
Randomization: The authors clearly state that participants
were randomly assigned to groups.
Double Blind: The authors clearly state that participants were
blind to the study group, and assessors were blind to partic-
ipant’s allocation.
Single Blind: The authors clearly state that participants were
blind to the study group or assessors were blind to partici-
pant’s allocation.
Independence of Assessors: The authors clearly state that
pre/post assessments and interventions were carried out by
different professionals.
Control Intervention: The authors clearly state that there was
a control intervention for comparison purposes tapping spe-
cific cognitive abilities.
Placebo Intervention: The authors clearly state that there was
a control intervention not tapping specific cognitive abilities.
Inclusion Criteria: The authors clearly state the criteria
needed to be included in the study.
Exclusion Criteria: The authors clearly state the criteria
needed to be excluded from the study.
Control of Selection Bias: The authors clearly state poten-
tial sources of bias at baseline and control them some way
(e.g., methodologically, statistically). This includes ana-
lyzing potential differences between groups on demo-
graphical and outcome variables used in the primary study
(e.g., age, sex, educational level, memory outcomes, etc.)
Follow-Up Assessment: The authors include a follow-up
assessment to check the generalization of any positive
finding.
Standardized Assessment: Standard tests and tasks were
used to measure cognitive functioning and/or memory.
Functional Assessment: Functional assessment was mea-
sured individually using functional questionnaires and
scales.
Detailed Explanation of the Intervention: The authors state
clearly the intervention used in the study. The intervention
explanation must include timing, type of exercises, some
example of the exercises, who was in charge of the inter-
vention, the cognitive domains covered, and individually/
group driven information to be considered a detailed ex-
planation.
Attrition Causes: The authors clearly state the initial sam-
ple size, the causes of attrition and sample mortality and
the final sample size.
(Appendices continue)
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Appendix B
Formulas for Meta-Analysis
Formulas for Correlational Meta-Analysis
zri
1
2Loge1  ri1  ri
ESz
 i1k wi*zri
 i1k wi*
.
wz
* 11
(n 3)
2
2 Q (k 1)
c
c
i1
k
(n 3) i1
k (n 3)2
 i1k (n 3)
Q
i1
k
wz
*(zriESz)2
SEESz 1 i1k wz*
ESr
e(2ESz) 1
e(2ESz) 1
Formulas for Meta-Analysis on Means
ES in the experimental group: dE  MPOST 	 MPRE/SDPRE
ES in the control group: dC  MPOST 	 MPRE/SDPRE
c(df) 1 34df 1[df n 1]
Adjusted dE  c(df)  dE
Adjusted dC  c(df)  dC
Effect size (ES): dE 	 dC
E
2 CE2[2(1 rE)n n 1n 31 ndE
2
2(1 r)] dE2
C
2 CC2 [2(1 rC)n n 1n 31 ndC
2
2(1 r)] dC2
ES
2 E
2 C
2
ESFE
wid
wi
wi
1
d
2
ES
2  1
wi
Confidence intervals  ES 
 1.96 * ES2
Hedges’ Q  kd
2
e
2 	df  k – 1

Observed variance e2 
wid  ES2
wi
Variance due to sampling error  k
i1k wi
I2 (Q – df) ⁄Q
2 Q dfC if Q df
0 if Q	 df
Cwiwi
2
wi
ESRE
wi*d
wi*
wi
* 1
d
22
(Appendices continue)
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Appendix C
Sensitivity Analysis
r ES
95% CI
VarLL UL
	0.9 0.29 0.43 0.15 0.00
	0.8 0.29 0.43 0.15 0.00
	0.7 0.29 0.42 0.15 0.00
	0.6 0.29 0.42 0.15 0.00
	0.5 0.29 0.42 0.16 0.00
	0.4 0.29 0.42 0.16 0.00
	0.3 0.29 0.42 0.16 0.00
	0.2 0.29 0.41 0.16 0.00
	0.1 0.29 0.41 0.16 0.00
0 0.29 0.41 0.16 0.00
0.1 0.28 0.41 0.16 0.00
0.2 0.28 0.40 0.16 0.00
0.3 0.28 0.40 0.16 0.00
0.4 0.28 0.39 0.17 0.00
0.5 0.28 0.39 0.17 0.00
0.6 0.27 0.38 0.17 0.00
0.7 0.27 0.37 0.17 0.00
0.8 0.26 0.36 0.17 0.00
0.9 0.26 0.35 0.17 0.00
Original 0.29 0.41 0.16 0.00
With mean r 0.27 0.37 0.17 0.00
Note. ES  effect size; CI  confidence interval; LL  lower limit; UL  upper limit; Var  variance.
Appendix D
Correlations Between Moderator Variables at the Study Level
Study characteristics 3 4 5 6 7
1. Random Y .095 	.095 	.095 .368 	.039
2. Random N 	.095 .095 .095 	.368 .039
3. I.Assess Y 1 	.321 .368 	.287
4. I.Assess N 1 .321 	.368 .287
5. C.Cogn 1 .587 .039
6. C.Plac 1 .630
7. C.Pharm 1
Note. N  19. Y  yes; N  no; I.Asses  Independence of assessors; C.Cogn  Control: cognitive group; C.Plac 
Control: placebo; C.Pharm  Control: pharma only or no intervention. Bold coefficients indicate p  .01.  1,2  	1; 
3,4  	1. The conclusions drawn from the table are as follows: (a) Studies with a cognitive stimulation control group had
a placebo control group less frequently; (b) studies with a placebo control group had a pharma only control group less
frequently; and (c) moderators are not collinear with each other at the study level.
(Appendices continue)
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Appendix E
Effect Size for Each Study and Outcome
Study Outcome Adjusted dtreatment Adjusted dcontrol d 2(d)
95% CI
LL UL
1. Heiss et al. (1993) MMSE 	0.36 	0.14 	0.21 0.13 	0.91 0.48
Verbal Selective reminding 0.33 	0.06 0.39 0.12 	0.30 1.09
MMSE 	0.11 	0.14 0.03 0.12 	0.65 0.70
Verbal Selective reminding 	0.23 	0.06 	0.16 0.12 	0.84 0.52
MMSE 0.40 	0.14 0.54 0.13 	0.16 1.25
Verbal Selective reminding 0.55 	0.06 0.61 0.14 	0.12 1.34
2. Heiss et al. (1994) MMSE 	0.26 	0.22 	0.05 0.07 	0.56 0.47
Verbal Selective reminding 0.30 0.06 0.24 0.07 	0.27 0.75
MMSE 	0.04 	0.22 0.18 0.07 	0.33 0.69
Verbal Selective reminding 0.11 0.06 0.05 0.07 	0.46 0.55
MMSE 0.26 	0.22 0.48 0.07 	0.03 0.99
Verbal Selective reminding 0.29 0.06 0.23 0.07 	0.27 0.75
3. Davis et al. (2001) MMSE 0.04 0.05 	0.01 0.06 	0.49 0.47
LM-Immediate 0.26 	0.04 0.30 0.06 	0.19 0.79
LM-Delayed 0.41 0.48 	0.07 0.07 	0.60 0.46
4. Farina et al. (2002) MMSE 0.46 0.17 0.29 0.13 	0.43 1.00
RBMT-SS 0.25 0.43 	0.17 0.13 	0.89 0.55
RBMT-PS 0.19 0.24 	0.05 0.12 	0.73 0.64
ADL (Katz) 	0.23 0.01 	0.23 0.12 	0.91 0.44
IADL (Lawton) 0.10 	0.10 0.20 0.12 	0.47 0.88
5. Cahn-Weiner et al. (2003) HVLT-Total learning 	0.08 	0.34 0.25 0.07 	0.27 0.77
HVLT-Delayed recall 	0.24 	0.29 0.05 0.07 	0.47 0.58
HVLT-Recognition 	0.13 	0.33 0.20 0.07 	0.32 0.72
ADL (Lawton) 	0.04 	0.02 	0.02 0.07 	0.52 0.48
6. Hofmann et al. (2003) MMSE 0.00 0.67 	0.67 0.16 	1.45 0.11
7. Loewenstein et al. (2004) Face-name assoc. 3 learning 1.29 0.38 0.91 0.09 0.31 1.51
Face-name assoc. Delayed 1.20 0.06 1.13 0.08 0.57 1.70
Bayer ADLSa 	0.34 	0.37 0.03 0.06 	0.44 0.50
8. Cipriani et al. (2006) MMSE 0.80 0.46 0.34 0.18 	0.49 1.17
RBMT-SS 0.19 0.55 	0.35 0.14 	1.09 0.38
AADL (Reuben)a 	0.07 0.00 	0.07 0.12 	0.74 0.60
9. Farina et al. (2006) MMSE 0.42 	0.03 0.44 0.08 	0.10 0.99
RBMT-PS 	0.03 	0.06 0.03 0.07 	0.49 0.55
RBMT-SS 0.26 0.07 0.19 0.07 	0.34 0.72
FLSA 0.12 0.22 	0.10 0.07 	0.63 0.43
ADL (Katz) 0.13 	0.35 0.48 0.08 	0.06 1.02
IADL (Lawton) 0.27 0.02 0.25 0.07 	0.28 0.78
10. Requena et al. (2006) MMSE 0.29 	0.43 0.72 0.06 0.22 1.21
ADAS-Coga 0.59 	0.51 1.10 0.07 0.57 1.63
MMSE 0.29 0.29 0.00 0.06 	0.49 0.50
ADAS-Coga 0.59 0.21 0.39 0.07 	0.13 0.91
MMSE 0.29 	1.22 1.51 0.11 0.85 2.16
ADAS-Coga 0.59 	1.00 1.59 0.10 0.97 2.22
11. Tárraga et al. (2006) ADAS-Coga 0.18 	0.19 0.36 0.08 	0.18 0.90
MMSE 0.66 0.04 0.62 0.09 0.03 1.21
Kurtz test 0.05 	0.34 0.39 0.08 	0.16 0.93
RBMT - Story Recall Imm 0.37 0.08 0.29 0.08 	0.26 0.84
ADAS-Coga 0.18 	0.39 0.57 0.09 	0.03 1.17
MMSE 0.66 	0.59 1.25 0.12 0.56 1.94
Kurtz test 0.05 0.22 	0.17 0.09 	0.75 0.41
12. Galante et al. (2007) MMSE 0.03 0.73 	0.70 0.60 	2.22 0.82
Prose memory 	0.02 0.08 	0.10 0.29 	1.16 0.96
BADL 0.09 	0.44 0.52 0.40 	0.72 1.76
IADL (Lawton) 	0.24 0.61 	0.84 0.51 	2.24 0.56
13. Clare et al. (2010) RBMT-PS 	0.06 	0.28 0.22 0.04 	0.16 0.60
RBMT-PS 	0.06 	0.04 	0.03 0.03 	0.36 0.31
14. Giordano et al. (2010) MMSE 0.53 0.09 0.43 0.03 0.12 0.74
ADAS-Coga 0.85 0.28 0.57 0.03 0.23 0.91
ADLa (No reference) 0.30 0.09 0.21 0.02 	0.09 0.51
IADLa (No reference) 	0.37 	0.20 	0.17 0.02 	0.48 0.13
15. Viola et al. (2011) MMSE 	0.03 	0.22 0.19 0.04 	0.23 0.60
SKTa 	0.04 	0.21 0.18 0.03 	0.17 0.52
Th
is
do
cu
m
en
ti
s
co
py
rig
ht
ed
by
th
e
A
m
er
ic
an
Ps
yc
ho
lo
gi
ca
lA
ss
oc
ia
tio
n
o
r
o
n
e
o
fi
ts
al
lie
d
pu
bl
ish
er
s.
Th
is
ar
tic
le
is
in
te
nd
ed
so
le
ly
fo
rt
he
pe
rs
on
al
u
se
o
ft
he
in
di
vi
du
al
u
se
r
an
d
is
n
o
t
to
be
di
ss
em
in
at
ed
br
oa
dl
y.
21COGNITIVE INTERVENTIONS IN AD: META-ANALYSIS
Appendix E (continued)
Study Outcome Adjusted dtreatment Adjusted dcontrol d 2(d)
95% CI
LL UL
16. Jelcic et al. (2012) MMSE 0.69 	0.37 1.05 0.07 0.52 1.59
Brief Stroy Recall-Immediate 0.48 0.30 0.18 0.07 	0.32 0.68
Brief Stroy Recall-Delayed 0.50 	0.07 0.57 0.06 0.08 1.06
RAVLT-Immediate 0.33 	0.02 0.36 0.06 	0.12 0.83
RAVLT-Delayed 0.46 	0.25 0.72 0.06 0.22 1.21
IADL (Lawton) 0.06 0.00 0.06 0.06 	0.40 0.52
17. Bergamaschi et al. (2013) MMSE 0.88 	1.69 2.57 0.24 1.61 3.53
Story Recall-immediate 0.33 	0.05 0.39 0.15 	0.37 1.14
ADL (Katz) 	0.26 	1.15 0.89 0.10 0.26 1.51
IADL (Lawton) 	0.14 	0.52 0.38 0.04 	0.02 0.77
18. Cotelli et al. (2014) MMSE 0.19 0.40 	0.20 0.15 	0.97 0.56
RBMT Story recall 	 Imm 0.62 0.00 0.62 0.31 	0.46 1.70
RBMT Story recall 	 Del. 1.55 0.40 1.15 0.43 	0.13 2.43
RAVLT Imm 0.15 0.27 	0.12 0.04 	0.53 0.29
RAVLT Del 0.80 0.10 0.70 0.16 	0.08 1.48
ADL (No reference) 	0.01 0.13 	0.14 0.07 	0.66 0.38
IADL (No reference) 	0.01 	0.01 0.00 0.09 	0.60 0.60
MMSE 0.19 0.08 0.11 0.13 	0.59 0.82
RBMT Story recall 	 Imm 0.62 0.47 0.16 0.29 	0.90 1.21
RAVLT Imm 0.15 0.38 	0.23 0.06 	0.71 0.25
RAVLT Del 0.80 0.31 0.49 0.23 	0.45 1.43
ADL (No reference) 	0.01 	0.27 0.26 0.08 	0.30 0.82
IADL (No reference) 	0.01 	0.29 0.29 0.09 	0.29 0.87
19. Fernández-Calvo et al. (2015) ADAS-Coga 0.18 	0.87 1.05 0.06 0.59 1.51
RDRS-2 0.09 	0.52 0.60 0.04 0.20 1.01
Note. RBMT  Rivermead Behavioral Memory Test; SS  Standard Score; PS  Profile Score; MMSE  Mini-Mental State Examination; ADL 
activities of daily living; IADL Instrumental ADL; AADL Advance ADL; LM Logical Memory subtest; RAVLT Rey Auditory Verbal Learning
Test; ADAS-Cog  Alzheimer’s Disease Assessment Scale–Cognitive subscale; SKT  Short Cognitive Test; RDRS  Rapid Disability Rating Scale–2.
a The sign of the effect size is inverted for comparison purposes as lower scores indicate improvement (ADAS-Cog) or slower decline (MMSE).
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